To determine the incidence, types and risk factors for infection in systemic lupus erythematosus (SLE) patients in Kuala Lumpur, Malaysia, we retrospectively reviewed the medical records of 102 patients with definite SLE attending a specialist clinic. Details of major infections (pneumonia or severe infection requiring intravenous therapy) and minor infections, and their time of onset in relation to immunosuppressive therapy and disease flares were recorded. There were 77 major and 163 minor infections during 564 patient-years of follow-up. In the month following a course of pulse methylprednisolone, the incidence of major infection was 20 times higher and the incidence of minor infection was 10 times higher than at other periods ( p < 0.0001). In the month after disease flare, the incidence of major infection was 10 times higher and the incidence of minor infection six times higher than at other times ( p < 0.0001). After allowing for methylprednisolone therapy and disease flares, there was no increase in the rate of infections during treatment with azathioprine, oral or intravenous cyclophosphamide. There was no effect of renal involvement on infection rate.
Introduction
A number of studies have established that systemic lupus erythematosus (SLE) is associated with a high rate of infection, and that infection contributes greatly to the morbidity and mortality of the disease. 1 The high rate of infection is thought to be partly an effect of the disease itself, as infection occurs more frequently than in similar groups of patients with other autoimmune diseases such as rheumatoid arthritis, 2 but the use of immunosuppressive agents to treat active lupus also contributes to the frequency of infection. Several studies have identified a significant increase in infection rate in patients treated with prednisolone, 2 ' 3 although others have not. 4 ' 5 Azathioprine has been shown not to cause an increase in infection rate. 3 None of the previous large cohort studies of infection in SLE have examined the effect of oral or intravenous cyclophosphamide or pulse methylprednisolone on the rate of infection. Almost all the previous studies of infection in SLE have been conducted in cohorts of patients in America, Canada or Europe. SLE is common in SE Asia, and it might be expected that, given the higher environmental exposure to potential pathogens, infection would play an even larger role in the morbidity and mortality of SLE patients in that region. It is thus surprising that apart from a small study in hospitalized patients in Singapore, 6 where standards of hygiene and public health are comparable to developed countries, there have been no cohort studies which have specifically examined infection in SLE patients in Asia.
We therefore investigated the frequency and types of infection in patients attending the National University of Malaysia SLE clinic in Kuala Lumpur, Malaysia. A large proportion of patients in Kuala Lumpur with SLE nephritis are referred for management at this centre, and many patients are treated with azathioprine, oral or intravenous cyclophosphamide and methylprednisolone in addition to oral corticosteroids. These patients are therefore an ideal group in whom to study the effects of immunosuppressive agents on infection. We also sought to examine the effects of disease flare, renal involvement, sex and socioeconomic status on the incidence of infection.
Methods
Case records for all the patients who had attended the SLE clinic at the National University of Malaysia between October 1978 and September 1993 were retrospectively reviewed by the same investigator. The clinical notes and laboratory results were examined in detail, and the features of lupus corresponding to the ARA criteria 7 were recorded (malar rash, discoid rash, photosensitivity, oral ulcers, arthritis, serositis, renal disorder, neurological disorder, haematological disorder, immunological disorder, antinuclear antibody). Renal involvement was defined as persistent proteinuria greater than 0.5 g/day or > 3 + (if quantitation not performed), or cellular casts on microscopy or findings on renal biopsy consistent with lupus nephritis. Background information was recorded on sex, race, age at diagnosis and duration of disease from diagnosis to last follow-up visit or death. The date of diagnosis was taken as the time when the diagnosis of SLE was first made on the basis of a characteristic clinical picture and/or immunological abnormalities. Patients were classified into one of two socioeconomic groups on the basis of information on education, employment and salary which was routinely recorded in the notes (Group A: educated beyond secondary school, either the patient or spouse employed in a skilled or semi-skilled occupation, monthly salary equal to or exceeding M$1000; Group B: none of these factors).
All episodes of infection occurring from the time of diagnosis or start of the study period to the time of death or study end were recorded. Major infections were defined as those requiring intravenous antibiotics, or a confirmed pneumonia. Minor infections were defined as those requiring oral or topical therapy and generally involved the skin, mucous membranes, lower urinary tract or genital tract. There were a number of cutaneous infections which were difficult to classify: if severe cellulitis or an abscess with significant constitutional upset were recorded in the notes, then it was deemed to be a major infection irrespective of treatment given; all other cutaneous infections were termed minor. An episode of major infection was only recorded if (a) there was clinical evidence of infection and microbiological identification of an organism or (b) both good clinical evidence of an infection, with radiological or laboratory tests supporting the presence of infection, and a response to antibiotics. A clinical diagnosis was sufficient to record an episode of minor infection. When two or more organisms were identified from one site, one episode of infection was recorded. When two organisms were recovered from different sites, they were considered as two separate infections.
The number of disease flares following diagnosis was recorded. A flare was counted if, following a period of disease quiescence, there was a marked exacerbation in previous symptoms, and/or clinical or laboratory evidence of rapid progression or new organ system involvement resulting in the need for an increase in the level of immunosuppression. Although patients were sometimes treated simultaneously for both presumed infection and a flare of disease, information on bacterial cultures, inflammatory markers and clinical outcome allowed the likely cause of symptoms to be determined with reasonable certainty on retrospective review of the notes.
The treatment charts were also examined and the duration and doses of azathioprine, oral and intravenous cyclophosphamide and number of courses of pulse methylprednisolone were recorded. The number of major and minor infections occurring during and in the month following cessation of treatment with each agent were noted for each patient. Virtually all the patients were treated with oral prednisolone, but due to frequently changing doses and poor compliance, we decided not to record details of treatment with oral corticosteroids.
The data was analysed using non-parametric tests throughout. Following Ginzler 3 the incidence of infection was expressed as the number of infections per 100 patient-years. The effect of individual factors on the rate of infection was determined by comparing the expected frequency of infection (calculated from the duration of observation and the overall rate of infection) with the observed frequency for patients or periods of follow-up with and without each factor. % 2 goodness of fit was used unless an expected frequency was less than five, in which case the binomial test was used. Because of the large number of comparisons made, a probability of less than 0.01 was regarded as significant.
Results

Inclusion of patients
In the 15-year period between October 1978 and September 1993, 155 patients were seen on at least one occasion in the SLE clinic. Records were available for 153 patients and of these, 51 patients were unsuitable for inclusion in the analysis: 25 patients had the majority of their care elsewhere and there was insufficient information to reliably determine the course of their illness, treatment or complications; five patients had an overlap syndrome, two patients had drug-induced lupus and the remaining 19 excluded patients were believed to have SLE but did not satisfy four ARA criteria.
Patient characteristics
The total duration of follow-up for the 102 eligible patients was 564 patient years. Four patients had been diagnosed prior to the study period, and had a mean duration of illness of 47 months prior to the start of the study. The racial distribution of the patients was 47% Chinese, 46% Malay and 7% Indian, 93% of patients were female, and 24% of all patients were classified as socioeconomic group A. Median age at diagnosis of SLE was 25 years (range 8-61 years). The mean number of ARA criteria satisfied was 5.2 (range 4-9) and there was a mean of 0.53 disease flares per patient per year.
Immunosuppressive therapy
A total of 76 courses of pulse methylprednisolone were given in 50 patients, the usual course being 250 mg (occasionally 500 mg) for three consecutive days. Pulse methylprednisolone was predominantly used on an ad hoc basis with the aim of achieving rapid disease control during relapse rather than as a regular regime for the treatment of lupus nephritis. Twenty-nine patients received low-dose intravenous pulse cyclophosphamide, usually for treatment of diffuse proliferative lupus nephritis. The standard regime of pulse cyclophosphamide was 250 mg weekly for 4 weeks, then monthly for 6 months, and if a good response was obtained, this was continued for up to 2 years. This regime was used to treat patients with active diffuse proliferative lupus nephritis considered to have a high risk of progressing to end-stage renal failure. Oral cyclophosphamide was given to 29 patients (nine of whom had been treated with intravenous cyclophosphamide earlier in the course of their disease) usually at doses of 100-150 mg daily for at least one year. Fifty-five patients were treated with oral azathioprine, most commonly at doses of 50-100 mg daily for periods of at least one year.
Infections
There were 77 major infections in total, an incidence of 13.7 infections per 100 patient-years of observation. The details of these infections are shown in Table 1 . A total of 163 minor infections occurred during the study period: an incidence of 28.9 infections per 100 patient-years. The most common minor infections were bacterial lower urinary tract infection (29), bacterial cutaneous infection (23), tinea corporis (12), herpes zoster (18), oral candidiasis (23), upper respiratory tract infection (32), gastroenteritis (5) and viral fever (5).
Risk factors for infection
Immunosuppressive treatment
In the month following treatment with pulse methylprednisolone the incidence of major infection was 20 times higher, and the incidence of minor infection 10 times higher, than at other times ( Table 2) . There was also a significantly higher rate of infection during treatment with intravenous cyclophosphamide (Table 3 ), but these infections nearly all occurred in the month following a course of methylprednisolone or in the month following a disease flare. When such infections were discounted, the apparent increase in infection rate during intravenous cyclophosphamide was abolished. There was no significant difference in the frequency of infection during periods when either azathioprine or oral cyclophosphamide were given, compared to periods when each drug was not given (Tables 4 and 5) .
As additional security, the analysis was repeated for the subset of 51 major infections in which microbiological identification of a pathogen was obtained. The observed to expected ratios were even more striking than those obtained when all 77 major infections were analysed, and the statistical signific 
Disease activity
The incidence of infection was significantly higher in the month following a disease flare than at other periods (Table 6 ). However, 18% of flares were treated with pulsed methylprednisolone. In order to determine the contributions of methylprednisolone and increased disease activity individually, the infections occurring in association with each factor were analysed separately (Table 7) . It can be seen that there were significant increases in infection rate in the month following a relapse which was not treated with methylprednisolone, as well as in the month following a course of methylprednisolone given when the disease had not relapsed. However, the largest increase in infection rate (to 480 infections per 100 patient years) occurred in the month following a disease flare which was treated with methylprednisolone. These conclusions were unchanged when the Incidence, observed number of infections per 100 patient-years of follow-up; MPRED + , infections in the month following treatment with methylprednisolone; MPRED -, infections at times other than the month following treatment with methylprednisolone; O/E, ratio of observed to expected number of infections.
analysis was repeated for the subgroup of 51 microbiologically-confirmed major infections.
Sex, socioeconomic status, renal involvement
There was a slight excess of infections in female patients which only reached significance when the total infections were compared (50 per 100 patientyears in females; p< 0.003). Patients classified in the lower socioeconomic group (Group B) had twice the incidence of major infection (15.9 per 100 patient-years) and a slightly increased incidence of minor infection compared with those in Group A; these differences did not reach significance. The presence of renal disease had no effect on the incidence of major and minor infections (rate of total infections was 42.7 per 100 patient-years for those Relapse + MPRED -, the month following a relapse of disease which had not been treated with pulse methylprednisolone; Relapse-MPRED+ , the month following a course of pulse methylprednisolone which was given when disease had not flared; Relapse + MPRED + , the month following a relapse of disease which had been treated with pulse methylprednisolone. Other abbreviations as Table 2. with and 42.2 per 100 patient-years for those without renal involvement).
Infection-related mortality
There were 11 deaths which were directly attributable to infection during the study period. Methylprednisolone had been given in the month prior to onset of infection in five of these patients, but there was also evidence of active lupus in all these cases.
Discussion
To our knowledge this is the first study of risk factors for infection in a cohort of SLE patients conducted in SE Asia. We found a rate of 13.7 major infections per 100 patient-years of follow up and an overall rate of infection of 37.8 per 100 patient years. Comparison of these rates with previous studies of infection in SLE from America, Canada and Europe is confounded by several factors: some studies are confined to in-patients, in whom the infection rate is invariably higher, and there is also substantial variability between studies in the degree to which minor infections are recorded. However, there are three studies on cohorts of out-patients which follow broadly similar methods to ours and with which comparisons, at least of the rate of major infections, can usefully be made. Lee et al. found a rate of 6.9 major infections per 100 patient years in Canadian patients 4 and an identical rate was seen in a cohort of patients in Sweden. 8 In a group of patients in Brooklyn, New York observed for 655 patient-years, Ginzler found 91 bacterial infections (excluding urinary tract infections) comparable to the 'major infections' recorded in our study; an incidence of 13.8 major infections per 100 patient years. 3 The population of patients in that study is described elsewhere as characterized by a disproportionate number of socioeconomically disadvantaged patients who were often lost to follow-up for protracted periods before returning for care, and with a questionable degree of compliance. 1 This population probably resembles our patients with SLE in Kuala Lumpur more closely than the patients in the Canadian and Swedish cohorts; it is interesting that the incidence of major infection recorded in Brooklyn and Kuala Lumpur is almost identical and twice that observed in SLE patients in Canada and Sweden. The spectrum of infections in our SLE patients resembles that seen in other series. Gram-negative and opportunistic bacterial pathogens were frequently seen (e.g. Nocardia, M. tuberculosis, Pseudomonas); apart from oral Candida which was common, and one case of cryptococcal meningitis, fungal and protozoal infections were not observed. Fungal and other non-bacterial opportunistic infections are often not identified until postmortem in immunosuppressed SLE patients; 9 none of our patients underwent a full post-mortem, and this may explain why severe fungal infections were not identified, although they almost certainly existed. Pneumocystis carinii pneumonia has previously been reported in patients with SLE in Kuala Lumpur 10 but was not diagnosed in our patients. Difficulties with isolation of pathogens as well as the retrospective nature of the study mean that, in spite of the strikingly high incidence of infections in our cohort, these figures are almost certainly an underestimate of the true problem.
In this study we found a highly significant effect of pulse methylprednisolone treatment on the rate of major and minor infections. No previous study of infection in SLE has specifically examined the effect of methylprednisolone on infection rate. However, several studies have shown that oral corticosteroids predispose to infection, and that the rate of infection increases with increasing doses of steroids.
2 ' 3 Ginzler found the rate of bacterial infections to be approximately eight times higher in patients taking 40-100 mg prednisolone compared with those taking no prednisolone. 3 We did not examine the effects of oral corticosteroids in this study, but it would appear from comparison of the rate of major infection following methylprednisolone in our study with the rate of major infection associated with oral prednisolone in the study by Ginzler, that the use of pulse methylprednisolone is associated with a further increase in the rate of infection over and above that which would be expected from the use of high-dose oral steroids alone. Whether the effects of pulse methylprednisolone are qualitatively or quantitatively different from those due to conventional oral corticosteroids alone is uncertain. There is some experimental evidence to suggest that large doses of corticosteroids have effects on inflammation and immunoregulation which are not observed at lower doses.
11
After allowing for infections associated with methylprednisolone treatment and disease flare, there was no increase in the rate of infection with intravenous cyclophosphamide. Previous studies of infection in SLE largely preceded the advent of intravenous cyclophosphamide therapy in SLE. However, there have been several trials of intravenous cyclophosphamide in lupus nephritis which have found no excess of major infections in patients so treated.
12 '
13
In a recent trial of pulse methylprednisolone vs. pulse cyclophosphamide in severe lupus nephritis, major infections were rare and not related to any particular therapy. 12 The lack of an apparent effect of high-dose pulse methylprednisolone on infection in that trial is hard to reconcile with our finding of a striking association between methylprednisolone and infection rate. There were, however, remarkably few infections in the nephritis trial and it may be that if it had been conducted in a population with a high overall infection rate, a difference in infections between treatments would have become apparent. Neither treatment with azathioprine nor oral cyclophosphamide were associated with an increase in the infection rate in our patients and this finding agrees with previous studies. 3 ' 13 There was a significant increase in the rate of infection in the month following a flare of disease activity. Examining periods following all flares which had not been treated with methylprednisolone, there was a six-fold higher incidence of major and minor infection compared with other intervals. Thus there appears to be an effect of disease activity which is independent of methylprednisolone therapy. However, we cannot determine from our data whether this increased incidence of infection is a result of higher doses of oral corticosteroid following a flare, or whether there is an independent effect of disease activity. Nived and co-workers found a significant increase in the number of bacterial infections in the 2 months following disease flares. 14 Ginzler and colleagues found an approximately 50% increase in infection rate during a period when disease had flared, but this effect disappeared when the effects of oral steroids were taken into account. 3 In support of the suggestion that infections are directly related to disease flares is the observation that overall disease activity as measured by the SLEDAI is significantly associated with infection in hospitalized patients independent of the steroid dose. 5 The immunosuppressive regimens used at the National University of Malaysia are somewhat less aggressive than those typically used in specialist centres in America and Europe, although they have been found to be effective for treatment of lupus nephritis in Malaysia. Concern over the risk of infection was the principal reason for adopting these low-dose protocols. Our finding that azathioprine and cyclophosphamide are not associated with an increase in infection rate should help to reassure physicians working in developing countries that these agents are safe to use, at least in relatively modest doses. However, attention should be paid to the risk of infection when using pulse methylprednisolone, especially in populations of SLE patients such as ours that have high background rates of infection.
